Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PAM | P19021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6150290 | 1.00 | HCAR2 (0.45) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL5681276 | 0.98 | HCAR2 (0.44) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL29148759 | 0.95 | HCAR2 (0.45) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL5064772 | 0.91 | HCAR2 (0.48) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL9749521 | 0.91 | HCAR2 (0.48) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL29074633 | 0.90 | HCAR2 (0.58) | HCAR2TSHRALDH1A1LMNAPAM | |
| SCHEMBL8030996 | 0.90 | HCAR2 (0.38) | HCAR2TSHRTP53EGLN1EGLN3 | |
| SCHEMBL18209636 | 0.89 | HCAR2 (0.59) | HCAR2TSHRALDH1A1LMNATDP1 | |
| SCHEMBL4012514 | 0.89 | HCAR2 (0.59) | HCAR2TSHRALDH1A1LMNATDP1 | |
| SCHEMBL668234 | 0.89 | HCAR2 (0.59) | HCAR2TSHRALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2017-07-13 | — | — | US | disclosed |
| US-20130253056-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | COMT, SNCA, SCLY | HCAR2 3751/4885TSHR 1844/4885TP53 2630/4885 |
| US-20130253056-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | COMT, SNCA, SCLY | HCAR2 3751/4885TSHR 1844/4885TP53 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.